Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort

Abstract Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giulia Di Lazzaro, Mariachiara Ricci, Giovanni Saggio, Giovanni Costantini, Tommaso Schirinzi, Mohammad Alwardat, Luca Pietrosanti, Martina Patera, Simona Scalise, Franco Giannini, Antonio Pisani
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/36fff3116f8a4b8fbf7c31657fbfb239
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:36fff3116f8a4b8fbf7c31657fbfb239
record_format	dspace
spelling	oai:doaj.org-article:36fff3116f8a4b8fbf7c31657fbfb2392021-12-02T18:34:02ZTechnology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort10.1038/s41531-021-00227-12373-8057https://doaj.org/article/36fff3116f8a4b8fbf7c31657fbfb2392021-09-01T00:00:00Zhttps://doi.org/10.1038/s41531-021-00227-1https://doaj.org/toc/2373-8057Abstract Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This work aims at identifying prognostic biomarkers in newly diagnosed PD patients and quantifying therapy-response. Forty de novo PD patients underwent clinical and technology-based kinematic assessments performing motor tasks (MDS-UPDRS part III) to assess tremor, bradykinesia, gait, and postural stability (T0). A visit after 6 months (T1) and a clinical and kinematic assessment after 12 months (T2) where scheduled. A clinical follow-up was provided between 30 and 36 months after the diagnosis (T3). We performed an ANOVA for repeated measures to compare patients’ kinematic features at baseline and at T2 to assess therapy response. Pearson correlation test was run between baseline kinematic features and UPDRS III score variation between T0 and T3, to select candidate kinematic prognostic biomarkers. A multiple linear regression model was created to predict the long-term motor outcome using T0 kinematic measures. All motor tasks significantly improved after the dopamine replacement therapy. A significant correlation was found between UPDRS scores variation and some baseline bradykinesia (toe tapping amplitude decrement, p = 0.009) and gait features (velocity of arms and legs, sit-to-stand time, p = 0.007; p = 0.009; p = 0.01, respectively). A linear regression model including four baseline kinematic features could significantly predict the motor outcome (p = 0.000214). Technology-based objective measures represent possible early and reproducible therapy-response and prognostic biomarkers.Giulia Di LazzaroMariachiara RicciGiovanni SaggioGiovanni CostantiniTommaso SchirinziMohammad AlwardatLuca PietrosantiMartina PateraSimona ScaliseFranco GianniniAntonio PisaniNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 7, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Giulia Di Lazzaro Mariachiara Ricci Giovanni Saggio Giovanni Costantini Tommaso Schirinzi Mohammad Alwardat Luca Pietrosanti Martina Patera Simona Scalise Franco Giannini Antonio Pisani Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
description	Abstract Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This work aims at identifying prognostic biomarkers in newly diagnosed PD patients and quantifying therapy-response. Forty de novo PD patients underwent clinical and technology-based kinematic assessments performing motor tasks (MDS-UPDRS part III) to assess tremor, bradykinesia, gait, and postural stability (T0). A visit after 6 months (T1) and a clinical and kinematic assessment after 12 months (T2) where scheduled. A clinical follow-up was provided between 30 and 36 months after the diagnosis (T3). We performed an ANOVA for repeated measures to compare patients’ kinematic features at baseline and at T2 to assess therapy response. Pearson correlation test was run between baseline kinematic features and UPDRS III score variation between T0 and T3, to select candidate kinematic prognostic biomarkers. A multiple linear regression model was created to predict the long-term motor outcome using T0 kinematic measures. All motor tasks significantly improved after the dopamine replacement therapy. A significant correlation was found between UPDRS scores variation and some baseline bradykinesia (toe tapping amplitude decrement, p = 0.009) and gait features (velocity of arms and legs, sit-to-stand time, p = 0.007; p = 0.009; p = 0.01, respectively). A linear regression model including four baseline kinematic features could significantly predict the motor outcome (p = 0.000214). Technology-based objective measures represent possible early and reproducible therapy-response and prognostic biomarkers.
format	article
author	Giulia Di Lazzaro Mariachiara Ricci Giovanni Saggio Giovanni Costantini Tommaso Schirinzi Mohammad Alwardat Luca Pietrosanti Martina Patera Simona Scalise Franco Giannini Antonio Pisani
author_facet	Giulia Di Lazzaro Mariachiara Ricci Giovanni Saggio Giovanni Costantini Tommaso Schirinzi Mohammad Alwardat Luca Pietrosanti Martina Patera Simona Scalise Franco Giannini Antonio Pisani
author_sort	Giulia Di Lazzaro
title	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
title_short	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
title_full	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
title_fullStr	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
title_full_unstemmed	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
title_sort	technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo parkinson’s disease cohort
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/36fff3116f8a4b8fbf7c31657fbfb239
work_keys_str_mv	AT giuliadilazzaro technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT mariachiararicci technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT giovannisaggio technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT giovannicostantini technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT tommasoschirinzi technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT mohammadalwardat technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT lucapietrosanti technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT martinapatera technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT simonascalise technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT francogiannini technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort AT antoniopisani technologybasedtherapyresponseandprognosticbiomarkersinaprospectivestudyofadenovoparkinsonsdiseasecohort
_version_	1718377912382521344

Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort

Ejemplares similares